In its recent decision, the PTAB (“the Board”)
determined that all challenged claims of U.S. Patent No. 10,301,638
B2 were unpatentable under 35 U.S.C. § 328(a) for lack of
written description and lack of enablement.
Commonwealth Scientific and Industrial Research Organization
(“Petitioner”) filed a Petition to institute a
post-grant review of claims 1-23 of the '638 patent owned by
BASF Plant Science GMBH (“Patent Owner”). The patent,
issued on May 28, 2019, relates to a process for the production of
eicosapentaenoic acid (“EPA”), docosapentaenoic acid
(“DPA”), and/or docosahexaenoic acid
(“DHA”) in transgenic plants, and to “oils,
lipids, and/or fatty acids which have been produced by the
process.” The patent describes that the yield of long-chain
polyunsaturated fatty acids “can be increased by expressing
an optimized Δ5-elongase sequence in transgenic plants”
and that the fatty acids produced by the process are present with a
content of, in each case, at least